Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oteo, J.
Right arrow Articles by Gómez-Garcés, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oteo, J.
Right arrow Articles by Gómez-Garcés, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 691-693
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates

J. Oteo, B. Aracil, J. I. Alós and J. L. Gómez-Garcés*

Servicio de Microbiología, Hospital de Móstoles, 28935 Móstoles, Madrid, Spain

Susceptibility to anti-anaerobic agents in the Bacteroides fragilis group varies according to the geographical region studied. In recent years there has been a reduction in the susceptibility of such isolates, particularly to antibiotics such as clindamycin and cefoxitin. The antimicrobial susceptibilities of 100 isolates of the B. fragilis group isolated in 1998 from faecal samples of healthy people to clindamycin and five other anti-anaerobic agents were determined. Meropenem, metronidazole and trovafloxacin showed excellent activity against all isolates. The efficacy of cefoxitin was low, with only 46% of isolates susceptible. A high prevalence of resistance to clindamycin (49% of isolates) was observed.

* Corresponding author. Tel: +34-1-6648750; Fax: +34-1-6471917; E-mail: jlgarces{at}microb.net


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
A. Katsandri, J. Papaparaskevas, A. Pantazatou, G. L. Petrikkos, G. Thomopoulos, D. P. Houhoula, and A. Avlamis
Two Cases of Infections Due to Multidrug-Resistant Bacteroides fragilis Group Strains.
J. Clin. Microbiol., September 1, 2006; 44(9): 3465 - 3467.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Oteo-Iglesias, J.-I. Alos, and J.-L. Gomez-Garces
Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group
J. Antimicrob. Chemother., December 1, 2002; 50(6): 1055 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
K. E. Aldridge and M. O'Brien
In Vitro Susceptibilities of the Bacteroides fragilis Group Species: Change in Isolation Rates Significantly Affects Overall Susceptibility Data
J. Clin. Microbiol., November 1, 2002; 40(11): 4349 - 4352.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. E. Aldridge, D. Ashcraft, K. Cambre, C. L. Pierson, S. G. Jenkins, and J. E. Rosenblatt
Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of Bacteroides fragilis Group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus Species
Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1238 - 1243.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.